A new pilot under BioMed X’s XBridge framework aims to connect Harvard investigators with pharmaceutical researchers through structured matchmaking and sponsored research agreements.
The milestone marks meaningful progress toward developing new therapeutic options for Alport syndrome, with first-patient dosing expected in early 2026.
A collaboration designed to overcome the limitations of cold-chain logistics by enabling safe, viable, and ready-to-use transport of microbiome-sensitive 3D skin constructs to customers worldwide.
The acquisition brings together two leaders in scientific software to provide end-to-end support from molecular design and analytical characterization to manufacturing quality control.